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ABSTRACT
The rate-limiting step to drug absorption is often dissolution from the dosage form, especially for poorly soluble com-
pounds. Two possibilities for improving the dissolution of these drugs are to increase the available surface area and to im-
prove their apparent solubilities under physiologically relevant conditions with surfactants as wetting agents. Albendazole 
(ABZ), one of the most effective broad-spectrum antihelminthic agents, has a very low aqueous solubility, which leads to an 
erratic availability. Solid dispersions (SD) with different amounts of carriers (P188 and PEG6000) were formulated to improve 
the ABZ dissolution rate. When the dissolution test is used to infer biopharmaceutical properties of the dosage form, it is es-
sential that the method simulates the gastrointestinal conditions. The objective of this study was to examine the applicabil-
ity of different dissolution media to the evaluation of ABZ and ABZ-SD dissolution rates. Dissolution profiles were performed 
by the official method (0.1 N HCl) and Simulated Gastric Fluid modified with a surfactant. Wetting was evaluated through 
the determination of surface tension and contact angle of the solutions. The dissolution rate of ABZ was clearly affected by 
the variables assessed in this study. These results have implications in the design of physiologically based dissolution media.
KEYWORDS: Albendazole; contact angle; surface tension; dissolution rate; solid dispersions.
INTRODUCTION
Dissolution testing is used to assess drug release rate from a dosage form, and it may provide a rational basis to predict in vivo behavior and dos-
age form optimization (1). The selection of the dissolu-
tion medium is based, in part, on drug solubility data 
and product dose range to ensure that sink conditions 
are met. On the other hand, when the dissolution test 
is used to infer the biopharmaceutical properties of the 
dosage form, a key experimental condition is that the 
proposed method simulates the gastrointestinal environ-
ment as much as possible (2). In spite of this, compendial 
dissolution media are usually far from representative of 
gastrointestinal tract conditions (3). The development 
of the Biopharmaceutics Classification System (BCS) has 
renewed interest in the compounding of physiologically 
relevant media for dissolution testing (4, 5). The lack of 
similarity between compendial methods for in vitro dis-
solution testing and physiologic conditions is reported 
as the main reason for the inability to predict in vivo 
dissolution from in vitro data (3). So, it would be highly 
desirable to develop media that more adequately reflect 
physiological conditions (6). In addition to pH, an impor-
tant characteristic of gastric fluids is the lower surface 
tension relative to water. Finholt et al. (7) examined the 
surface tension of human gastric juice and concluded 
that the value is nearly independent of pH and secre-
tion rate, lying normally in the range of 35–45 mN/m, 
while the surface tension of water is 72.8 mN/m. On the 
other hand, Luner et al. (8) studied the wetting proper-
ties of dispersions composed of dominant surface-active 
species found in the stomach at physiologically relevant 
concentrations, taking into account that in the fasted 
state, concentrations of bile salts in the gastric fluid, pre-
sumably present due to reflux from the duodenum, are 
in the range of 0.01–0.08 mM. In this sense, the authors 
studied different simulated gastric fluids and concluded 
that a given surfactant used to produce wetting similar 
to in vivo systems may indeed show characteristically 
different behavior for a particular surface. Consequently, 
when selecting a surfactant to emulate the properties 
of gastric fluids for a particular surface, it may be use-
ful to compare the wetting effect of a surfactant-based 
dissolution medium to that of media simulating in vivo 
conditions to ensure that a reasonable correspondence 
in wetting properties is achieved.*Corresponding author.
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The main possibilities for improving the dissolution of 
poorly soluble drugs are:
• Increase the available surface area by decreasing the 
solid particle size, by optimizing the wetting characteris-
tics of the compound surface, or both.
• Decrease the boundary layer thickness.
• Ensure sink conditions for dissolution.
• Improve the apparent solubility of the drug under physi-
ologically relevant conditions (9).
In the 1990s, the Food and Drug Administration (FDA) 
promoted the use of surfactants in dissolution media 
for poorly soluble drugs (8). It has been suggested that 
for poorly soluble compounds, inclusion of synthetic or 
biological surfactants in dissolution media is important to 
simulate a biological environment. Thus, in vitro dissolution 
would be more representative of in vivo rates (3, 10, 11).
The mechanism by which a surfactant increases the dis-
solution rate is complex. Surfactants generally improve wet-
ting by reducing the interfacial energy for the liquid–vapor 
interface and adsorbing on the substrate to cause a reduc-
tion in the interfacial energy for the solid–liquid interface. 
However, some authors (12–15) have demonstrated a solu-
bilizing effect at concentrations below the critical micellar 
concentration (CMC). A better understanding of the wetting 
properties of biorelevant media is necessary to rationally 
formulate dissolution media that accurately account for the 
critical factors involved in the dissolution process (8).
The drug under investigation in this study was alben-
dazole (ABZ), a low aqueous solubility (0.01 mg/mL in 
water at 25 °C) and high permeability antihelminthic 
agent that belongs to BCS Class 2 (16). The unsatisfactory 
ABZ dissolution rate limits its absorption; therefore, it is 
poorly and erratically absorbed from the gastrointestinal 
tract. In vivo studies (17, 18) have demonstrated that the 
oral absorption of benzimidazole compounds depends 
on their dissolution at low pH and is closely related to 
the rate of gastric emptying and gut transit time. The USP 
indicates that the dissolution medium used to evaluate 
ABZ dissolution is 0.1 N HCl (19). However, this does not 
reflect the most relevant physiological conditions of the 
gastrointestinal tract.
The improvement of dissolution rates may be addressed 
by mean of different technological strategies. Among them, 
the design of solid dispersions (SD) has acquired notable 
attention (20–22). An SD is defined as the dispersion of one 
or more active ingredients in inert carriers in the solid state 
prepared by fusion, solvent, or solvent–fusion methods (23).
Misleading results can be concluded from in vitro re-
lease rates of SDs if the test conditions do not adequately 
simulate the gastrointestinal conditions (9).
In this framework, the aim of this work was to evalu-
ate the effect of interfacial properties of different dis-
solution media on the dissolution rate of ABZ and SDs 
containing ABZ.
MATERIALS AND METHODS
Preparation of Solid Dispersions
ABZ (pharmaceutical grade, Parafarm, Buenos Aires, 
Argentina), Poloxamer 188 (P188, BASF, Germany), and 
Polyethylene Glycol 6000 (PEG6000, Fluka, Germany) were 
used for the preparation of SDs.
SDs were prepared by melting different proportions 
of ABZ and carrier (Table 1) in a heating circulator water 
bath at 63 °C for P188 and 68 °C for PEG6000. The mixtures 
were homogenized by stirring, cooled, and pulverized. 
The 212-µm particle size fraction was obtained by sieving 
and kept in a screw-capped glass vial at 2–8 °C until use.
XRP Diffraction and IR Spectroscopy
Powder X-ray diffraction was performed using a Rigaku 
Miniflex 2000 diffractomer (λ: 1.5418 Å with a Bragg–Bren-
tano geometry). The radiation was generated by a Cu Kα 
lamp. The instrument was operated in the continuous 
scan mode with the scanning speed at 2°/min. The scan 
range was 3–70° 2θ/θ with a scan speed 0.066° 2θ/s. The 
solid dispersions and their respective physical mixtures 
were also characterized by IR spectroscopy (FT; Nicolet 
5SXC FTIR Spectrometer) using KBr disks.
Determination of Surface Tension
Surface tension measurements were conducted using 
the du Noüy method. Calibration was performed prior to 
use of the instrument and then verified using distilled wa-
ter. The solutions were maintained at 37.0 ± 0.3 °C using a 
heating circulator water bath.
Three separate measurements were made on separate 
aliquots of each of the following solutions: (1) 0.1 N hydro-
chloric acid; (2) modified simulated gastric fluid (mSGF) pH 
1.2 without pepsin, with 0.25% w/v sodium lauryl sulfate 
(24); and (3) solutions of both media with different con-
centrations (0.65, 1.95, 5.82, and 12.1 × 10-5 M) of each car-
rier. A wide range was selected to evaluate the influence 
of the carrier concentration on the dissolution media.
Contact Angle Determination
A rough estimation of hydrophobic drug wettability 
could be obtained by liquid–solid interface contact angle 
measurement (3). This assay was performed on compact-
ed powders (ABZ, carriers, and SD) using a homemade 
goniometer equipped with an image analysis attachment. 
The wetting liquid was contained in a 50-µL micropipette 
TABLE 1. Composition of Solid Dispersions
Solid Dispersion ABZ (% w/w) Carriera (%w/w)
SD1 5 95
SD2 10 90
SD3 25 75
SD4 50 50
a P188 or PEG600
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(Boeco, Germany); the discharge height was 2.00 ± 0.02 
mm and was regulated by a micrometer of 0.01-mm reso-
lution. Parameters such as drop volume, base diameter, 
and contact angle were recorded as a function of time, us-
ing specific software (ImageJ: Drop analysis – DropSnake). 
The procedure was performed in quadruplicate.
Dissolution Test
Dissolution tests of powdered SDs containing 50 mg of 
ABZ were carried out on a suitably calibrated USP Ap-
paratus 2 (Sotax AT7 Smart) at 50 ± 1 rpm, using 900 mL 
of dissolution medium at 37.0 ± 0.5 °C. The dissolution 
media were 0.1 N HCl and mSGF (19, 24). Samples (5 mL) 
were withdrawn at predetermined time intervals within 
one hour, with replacement of the same volume of fresh 
medium after each withdrawal. Previous results indicated 
that ABZ incorporated in SDs was rapidly released and 
reached steady state at 48–72 h (25). The samples were fil-
tered through a nylon membrane disposable filter (25-mm 
diameter, 0.45-µm pore size, Microclar, Argentine), which 
was validated for the absence of filter adsorption. Samples 
were suitably diluted and analyzed using UV spectropho-
tometry (Thermo Evolution 300) at 297 nm (λmax for 0.1 N 
HCl) and 307 nm (λmax for mSGF). The dissolution tests were 
performed in triplicate. In a previous work (26), the absence 
of interference on the ABZ λmax in the presence of dissolved 
carriers was verified. The concentration in each sample was 
calculated from an ABZ standard calibration curve. Results 
were averaged, and cumulative drug release percentages 
were calculated for dissolution profile estimation.
RESULTS AND DISCUSSION
XRP Diffraction and IR Spectroscopy
XRD diffractograms for the systems ABZ/P188 and ABZ/
PEG6000 are shown in Figure 1. Some signals allowed us 
to identify each component, ABZ (θ/2θ): 6.96, 11.37, 17.91, 
22.12, 24.58; P188 (θ/2θ): 19.32, 23.46; and PEG6000 (θ/2θ): 
19.20, 23.50.
Diffractograms from SDs clearly showed that the signals 
assigned to each component were practically unchanged. 
Thus, no interactions between them were detected, 
although SDs evidenced a slight reduction in cristallinity, 
especially at a high drug/carrier ratio (SD1).
The ABZ spectrum shows an N–H stretching vibration 
at 3,324.94 cm−1 and a bending vibration at 1,653.07 cm−1 
(Figure 2). The signals at these wavenumbers remain unal-
tered for SDs. In this way, the infrared spectra confirm that 
there were no chemical interactions between ABZ and carri-
ers (P188 or PEG6000) because of their close contact in SDs.
Determination of Surface Tension
The surface tension obtained for 0.1 N HCl was 54.29 
mJ/m, while for mSGF was 34.30 mJ/m, similar to that of 
gastrointestinal fluid (24). The surface tension was also 
measured at increasing concentrations of carrier (Figures 
3 and 4). For mSGF, surface tension was not affected by 
Figure 1. X-ray diffractograms of ABZ, P188, PEG6000, and SDs.
Figure 2. IR spectra of ABZ and SDs in (A) PEG6000 and (B) P188.
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the presence of PEG6000 or P188. On the other hand, for 
0.1 N HCl, the surface tension increased incrementally at 
increasing concentrations of PEG6000 until 1 × 10-5 M, fol-
lowed by a decrease (Figure 3). This effect was studied by 
Hillgren and Aldén (27), who described PEG as a nonionic 
water-soluble polymer with poor surface activity at low 
concentrations. However, at higher concentration, the sur-
face tension begins to decrease. This effect was attributed 
to the CH2CH2 groups, which are sufficiently hydrophobic 
to form an adsorbed layer from a PEG solution and orga-
nize a spreading monolayer at the air–water interface (28). 
It is important to note that the surface tension for 0.1 N 
HCl with PEG6000 was greater than for mSGF.
On the other hand, the surface tension decreases at in-
creasing concentrations of P188 in 0.1 N HCl (CMC 1.25 × 10-4 
M) due to the surfactant properties of this carrier (29). Never-
theless, the surface tension values were still higher for 0.1 N 
HCl than for mSGF in the presence of P188 (Figure 4).
Contact Angle Determination
ABZ showed very low wettability (α ≈ 90º), which in-
creased significantly when the drug was incorporated in 
SDs due to the presence of the carrier (Figure 5).
It is expected that this improvement in water affinity leads 
to a faster drug dissolution, especially at the earlier stage of 
the dissolution process. This behavior may be attributed to 
the change in the hydrodynamic environment of the media 
produced by the presence of the hydrophilic polymer, which 
is able to reduce the diffusion layer thickness (30).
Dissolution Tests
The ABZ dissolution performance was somewhat im-
proved with the use of mSGF, compared with the dissolu-
tion rate obtained in 0.1 N HCl (Figure 6). Moreover, the 
ABZ dissolution was also improved with the formulation 
of SDs, especially with P188 as carrier where the smallest 
contact angle was observed. This phenomenon can be 
attributed to an improvement of ABZ particle wettabil-
ity, regardless of the presence of carrier. When an SD was 
formulated with PEG6000, the dissolution was particularly 
improved for SD1 and SD2 (Figure 6).
The SDs dissolution profiles in both dissolution media 
are shown in Figure 6. The results show that the dissolu-
tion was clearly different in both media, which confirms 
the primary hypothesis of this work. The dissolution rate 
of SDs with P188 as carrier was higher in mSGF than in 
0.1 N HCl in almost all cases. This is due to the presence of 
a surfactant, which reduced the surface tension, promot-
ing the particle wettability, and therefore its dissolution. 
A similar behavior was observed for SDs prepared with 
PEG6000, at lower ABZ concentrations and higher carrier 
concentrations (SD1 and SD2), due to the dependence of 
the dissolution rate on carrier concentration.
Figure 4. Surface tension of different dissolution media at increasing P188 
concentrations.
Figure 5. Determination of contact angle of ABZ, carriers, and SDs 
(PEG6000 or P188 with increasing concentrations of ABZ).
Figure 3. Surface tension of different dissolution media at increasing 
PEG6000 concentrations.
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CONCLUSION
The present study reveals that ABZ dissolution charac-
teristics vary widely depending on the dissolution media. 
This can be attributed to a lower surface tension of the 
alternative dissolution medium (i.e., with SLS), which 
favors the wettability of the drug and, therefore, im-
proves the ABZ dissolution rate. This kind of information 
may be useful in the proposal of official monographs for 
dissolution assays that resemble physiological condi-
tions. On the other hand, SDs containing ABZ and P188 
or PEG6000 as carriers showed a significant increase in 
drug dissolution rate, which confirms the suitability of 
this technology for dissolution improvement of a Class 2 
active ingredient.
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